These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 10658903

  • 1. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
    Tubbs RR, Stoler MH.
    Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
    [No Abstract] [Full Text] [Related]

  • 2. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
    Hugh J, Barley R, Dabbagh L.
    Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Luminal B breast tumors are not HER2 positive.
    Bhargava R, Dabbs DJ.
    Breast Cancer Res; 2008 Mar; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ.
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [Abstract] [Full Text] [Related]

  • 6. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL, Jamehdor MR, Arber JM.
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K, Han S, Kim HJ, Kim J, Shin E.
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.
    Allred DC.
    J Natl Cancer Inst; 2010 May 05; 102(9):585-7. PubMed ID: 20427432
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV, Mohammed WA, Ragoonanan C, Omo-Igbinomwanhia NE.
    West Indian Med J; 2002 Mar 05; 51(1):4-9. PubMed ID: 12089875
    [Abstract] [Full Text] [Related]

  • 16. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H.
    Mod Pathol; 2002 Feb 05; 15(2):116-24. PubMed ID: 11850540
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.